Table 1.
Effective dose from the 55 radiopharmaceuticals in ICRP publication 106, determined using three different methods
| (E/A 0)1 [mSv/MBq] | (E/A 0)2 [mSv/MBq] | ((E/A 0)2 − (E/A 0)1)/(E/A 0)1 [%] | (E/A 0)3 [mSv/MBq] | ((E/A 0)3 − (E/A 0)1)/(E/A 0)1[%] | (E/A 0)3 male [mSv/MBq] | (E/A 0)3 female [mSv/MBq] | |
|---|---|---|---|---|---|---|---|
| Phantom | MIRD | ICRP/ICRU | ICRP/ICRU | ICRP/ICRU | ICRP/ICRU | ||
| w T | ICRP 60 | ICRP 60 | ICRP 103 | ICRP 103 | ICRP 103 | ||
| Radiopharmaceuticals | |||||||
| 3H Tritium-labelled neutral fat & free fatty acids | 2.2E-01 | 9.34E-02 | −58 | 1.72E-01 | −22 | 2.38E-01 | 1.05E-01 |
| 11C Carbon acetate | 3.5E-03 | 4.37E-03 | 25 | 4.20E-03 | 20 | 4.08E-03 | 4.31E-03 |
| 11C Carbon amino acids | 5.6E-03 | 4.43E-03 | −21 | 4.62E-03 | −18 | 4.89E-03 | 4.34E-03 |
| 11C Carbon brain receptor substances | 4.3E-03 | 3.22E-03 | −25 | 3.56E-03 | −17 | 3.69E-03 | 3.42E-03 |
| 11C Carbon methionine | 8.4E-03 | 5.39E-03 | −36 | 5.49E-03 | −35 | 5.69E-03 | 5.28E-03 |
| 11C Carbon (2-11C)thymidine | 2.7E-03 | 2.36E-03 | −13 | 2.53E-03 | −6 | 2.61E-03 | 2.45E-03 |
| 11C Carbon, realistic maximum | 1.1E-02 | 4.99E-03 | −55 | 5.46E-03 | −50 | 6.12E-03 | 4.79E-03 |
| 14C Carbon-labelled neutral fat and free fatty acids | 2.1E + 00 | 1.75E + 00 | −17 | 2.75E + 00 | 31 | 3.37E + 00 | 2.16E + 00 |
| 14C Carbon-labelled urea, normal case, orally administered | 3.1E-02 | 2.32E-02 | −25 | 2.65E-02 | −15 | 2.64E-02 | 2.66E-02 |
| 15O Oxygen water | 1.1E-03 | 9.07E-04 | −18 | 8.29E-04 | −25 | 8.30E-04 | 8.29E-04 |
| 18F Fluoride-labelled amino acids | 2.3E-02 | 1.75E-02 | −24 | 1.86E-02 | −19 | 1.97E-02 | 1.74E-02 |
| 18F Fluoride-labelled brain receptor substances | 2.8E-02 | 1.89E-02 | −33 | 1.91E-02 | −32 | 1.93E-02 | 1.89E-02 |
| 18F Fluoride FDG | 1.9E-02 | 1.50E-02 | −21 | 1.59E-02 | −16 | 1.66E-02 | 1.53E-02 |
| 18F Fluoride l-dopa | 2.5E-02 | 1.51E-02 | −40 | 1.68E-02 | −33 | 1.85E-02 | 1.52E-02 |
| 51Cr Chromium EDTA | 2.0E-03 | 1.39E-03 | −31 | 1.56E-03 | −22 | 1.76E-03 | 1.36E-03 |
| 67Ga Gallium citrate | 1.0E-01 | 7.66E-02 | −23 | 8.59E-02 | −14 | 8.58E-02 | 8.59E-02 |
| 68Ga Gallium-labelled EDTA | 4.0E-02 | 2.35E-02 | −41 | 2.37E-02 | −41 | 2.45E-02 | 2.29E-02 |
| 75Se Selenium-labelled amino acids | 2.2E + 00 | 2.03E + 00 | −8 | 2.21E + 00 | 0 | 2.33E + 00 | 2.09E + 00 |
| 75Se Selenium-labelled bile acid SeHCAT | 6.9E-01 | 2.37E-01 | −66 | 2.77E-01 | −60 | 2.76E-01 | 2.77E-01 |
| 99mTc Technetium apcitide | 4.7E-03 | 1.90E-03 | −60 | 2.05E-03 | −56 | 2.01E-03 | 2.09E-03 |
| 99mTc Technetium-labelled small colloids, intratumoural adm. time to removal 18 h | 2.0E-03 | 3.14E-03 | 57 | 3.96E-03 | 98 | 3.49E-03 | 4.43E-03 |
| 99mTc Technetium-labelled small colloids, intratumoural adm time to removal 6 h | 1.2E-03 | 1.78E-03 | 48 | 2.24E-03 | 87 | 1.98E-03 | 2.50E-03 |
| 99mTc Technetium EC, normal renal function | 6.3E-03 | 3.69E-03 | −41 | 4.23E-03 | −33 | 5.12E-03 | 3.33E-03 |
| 99mTc Technetium ECD | 7.7E-03 | 5.36E-03 | −30 | 5.75E-03 | −25 | 6.13E-03 | 5.36E-03 |
| 99mTc Technetium furifosmin, exercise | 8.9E-03 | 6.25E-03 | −30 | 6.67E-03 | −25 | 6.73E-03 | 6.60E-03 |
| 99mTc Technetium furifosmin, resting subject | 1.0E-02 | 6.53E-03 | −35 | 6.99E-03 | −30 | 7.07E-03 | 6.91E-03 |
| 99mTc Technetium-labelled HIG | 7.0E-03 | 4.72E-03 | −33 | 4.59E-03 | −34 | 4.89E-03 | 4.29E-03 |
| 99mTc Technetium-labelled HM-PAO | 9.3E-03 | 1.06E-02 | 14 | 1.01E-02 | 9 | 9.93E-03 | 1.04E-02 |
| Tc-99 m Technetium-labelled IDA derivatives, normal hepato-biliary conditions | 1.7E-02 | 7.70E-03 | −55 | 8.62E-03 | −49 | 8.58E-03 | 8.66E-03 |
| 99mTc Technetium-labelled MAA | 1.1E-02 | 1.29E-02 | 17 | 1.02E-02 | −7 | 9.54E-03 | 1.08E-02 |
| 99mTc Technetium-labelled MAG3, normal renal function | 7.0E-03 | 4.05E-03 | −42 | 4.65E-03 | −34 | 5.68E-03 | 3.62E-03 |
| 99mTc Technetium-labelled non-absorbable markers, orally administered fluids | 1.9E-02 | 9.88E-03 | −48 | 1.06E-02 | −44 | 1.04E-02 | 1.08E-02 |
| 99mTc Technetium-labelled non-absorbable markers, orally administered solids | 2.4E-02 | 1.08E-02 | −55 | 1.14E-02 | −53 | 1.11E-02 | 1.18E-02 |
| 99mTc Technetium-labelled MIBI, exercise | 9.0E-03 | 6.06E-03 | −33 | 6.55E-03 | −27 | 6.57E-03 | 6.52E-03 |
| 99mTc Technetium-labelled MIBI, resting subject | 7.9E-03 | 6.58E-03 | −17 | 7.03E-03 | −11 | 6.95E-03 | 7.11E-03 |
| 99mTc Technetium-labelled monoclonal antibodies, intact antibody | 1.2E-02 | 8.27E-03 | −31 | 8.18E-03 | −32 | 7.95E-03 | 8.40E-03 |
| 99mTc Technetium pertechnegas | 1.2E-02 | 1.46E-02 | 22 | 1.46E-02 | 22 | 1.41E-02 | 1.50E-02 |
| 99mTc Technetium pertechnetate, intravenous blocking agent given | 4.2E-03 | 3.66E-03 | −13 | 4.12E-03 | −2 | 4.47E-03 | 3.78E-03 |
| 99mTc Technetium pertechnetate, intravenous no blocking agent given | 1.3E-02 | 1.55E-02 | 19 | 1.59E-02 | 22 | 1.55E-02 | 1.64E-02 |
| 99mTc Technetium pertechnetate orally, no blocking agent | 1.4E-02 | 6.02E-03 | −57 | 6.38E-03 | −54 | 6.33E-03 | 6.43E-03 |
| 99mTc Technetium-labelled phosphates and phosphonates, normal uptake and excretion | 5.8E-03 | 3.80E-03 | −34 | 4.31E-03 | −26 | 4.86E-03 | 3.75E-03 |
| 99mTc Technetium-labelled erythrocytes | 7.0E-03 | 2.57E-03 | −63 | 2.69E-03 | −62 | 2.67E-03 | 2.71E-03 |
| 99mTc Technetium technegas | 1.5E-02 | 1.87E-02 | 25 | 1.36E-02 | −9 | 1.24E-02 | 1.49E-02 |
| 99mTc Technetium tetrofosmin, exercise | 6.9E-03 | 5.18E-03 | −25 | 5.76E-03 | −17 | 5.86E-03 | 5.66E-03 |
| 99mTc Technetium tetrofosmin, resting subject | 8.0E-03 | 5.84E-03 | −27 | 6.29E-03 | −21 | 6.36E-03 | 6.22E-03 |
| 99mTc Technetium-labelled white blood cells (leukocytes) | 1.1E-02 | 9.60E-03 | −13 | 7.17E-03 | −35 | 6.81E-03 | 7.54E-03 |
| 111In Indium-labelled HIG | 1.7E-01 | 1.39E-01 | −18 | 1.41E-01 | −17 | 1.44E-01 | 1.38E-01 |
| 111In Indium-labelled monoclonal antibodies, intact antibody | 3.3E-01 | 2.14E-01 | −35 | 2.24E-01 | −32 | 2.17E-01 | 2.32E-01 |
| 111In Indium octreotide | 5.4E-02 | 8.02E-02 | 49 | 6.87E-02 | 27 | 6.79E-02 | 6.96E-02 |
| 123I Iodide, thyroid uptake 35% | 2.2E-01 | 2.72E-01 | 24 | 2.33E-01 | 6 | 2.12E-01 | 2.53E-01 |
| 123I Iodine BMIPP | 1.6E-02 | 1.37E-02 | −14 | 1.57E-02 | −2 | 1.62E-02 | 1.52E-02 |
| 123I Iodine IPPA | 1.6E-02 | 1.38E-02 | −14 | 1.58E-02 | −1 | 1.63E-02 | 1.53E-02 |
| 123I Iodine-labelled brain receptor substances | 5.0E-02 | 3.33E-02 | −33 | 3.30E-02 | −34 | 3.18E-02 | 3.43E-02 |
| 123I Iodine Hippuran, normal renal function | 1.2E-02 | 7.41E-03 | −38 | 8.32E-03 | −31 | 1.00E-02 | 6.62E-03 |
| 123I Iodine MIBG | 1.3E-02 | 1.14E-02 | −12 | 1.32E-02 | 2 | 1.36E-02 | 1.27E-02 |
| 123I Iodine-labelled monoclonal antibodies, intact antibody | 2.9E-02 | 2.33E-02 | −20 | 2.18E-02 | −25 | 1.11E-03 | 1.24E-03 |
| 124I Iodide, thyroid uptake 35% | 1.5E + 01 | 1.51E + 01 | 1 | 1.28E + 01 | −15 | 1.14E + 01 | 1.41E + 01 |
| 125I Iodide, thyroid uptake 35% | 1.4E + 01 | 1.98E + 01 | 41 | 1.66E + 01 | 19 | 1.50E + 01 | 1.83E + 01 |
| 131I Iodide, thyroid uptake 35% | 2.4E + 01 | 2.72E + 01 | 13 | 2.22E + 01 | −8 | 2.03E + 01 | 2.41E + 01 |
| 131I Iodine, Hippuran, normal renal function | 5.2E-02 | 1.65E-02 | −68 | 1.80E-02 | −65 | 2.10E-02 | 1.51E-02 |
| 131I Iodine-labelled monoclonal antibodies, intact antibody | 4.7E-01 | 3.13E-01 | −33 | 2.57E-01 | −45 | 2.49E-01 | 2.66E-01 |
| 131I Iodine NP59 | 1.8E + 00 | 1.94E + 00 | 8 | 1.73E + 00 | −4 | 1.62E + 00 | 1.84E + 00 |
| 201Tl Thallium ion | 1.4E-01 | 1.21E-01 | −14 | 1.02E-01 | −27 | 1.07E-01 | 9.76E-02 |
(E/A0)1 is the previously published effective dose per unit administered activity (E/A0) by ICRP, (E/A0)2 is (E/A0) dose calculated with the new phantoms and old tissue weighting factors while (E/A0)3 is with the new phantoms and new weighting factors. (E/A0)2 − (E/A0)1))/(E/A0)1 and ((E/A0)3 − (E/A0)1)/(E/A0)1 is the difference in percentage (%) of the new values compared to the old. (E/A0)3 male and (E/A0)3 female are the estimations generated from the equivalent dose of each gender separately using the new phantoms and new weighting factors.